MJoTAtalks

Dr Susanna's guide to

www.MJoTA.org
click here

www.MJoTAtalks.org click here

www.drsusanna.org click here



Dr Susanna loves the countries and the peoples of Africa
 
Bookmark and Share
Diabetes news from the American Diabetes Association

RSS Feed is unavailable or empty.
Diabetes News
Diabetes news from the National Institutes of Health Diabetes Educators.

RSS Feed is unavailable or empty.
Clinical trials testing therapies for diabetes

Latest Top (10) News


177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
<b>Conditions</b>: Thyroid Cancer <br/><b>Interventions</b>: Diagnostic Test: 68Ga-DOTA-TATE PET Scan; Other: Amino acid infusions; Drug: 177Lu-DOTA-EB-TATE <br/><b>Sponsors</b>: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) <br/><b>Not yet recruiting</b>
Tue, 17 Nov 2026 00:00:00 EST

4-7-8 Breathing Exercises for Stress, Well-Being, and Quality of Life in Newly Diagnosed Type 2 Diabetes
<b>Conditions</b>: Type 2 Diabetes Mellitus (DM) <br/><b>Interventions</b>: Behavioral: 4-7-8 Breathing Exercise <br/><b>Sponsors</b>: Artvin Coruh University <br/><b>Not yet recruiting</b>
Tue, 17 Nov 2026 00:00:00 EST

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
<b>Conditions</b>: Hyperlipidemia <br/><b>Interventions</b>: Drug: Enlicitide; Drug: Rosuvastatin; Drug: Placebo for Enlicitide; Drug: Placebo for Rosuvastatin <br/><b>Sponsors</b>: Merck Sharp & Dohme LLC <br/><b>Completed</b>
Tue, 17 Nov 2026 00:00:00 EST

A Natural History of Cardiometabolic Disease Among US Bhutanese: Developing the Cross-Sectional Bhutanese Community of Central Ohio Health Study to Understand Acculturation as Synergizing Socioenvironmental and Biobehavioral Risk Factors Propagating ...
<b>Conditions</b>: Cardiometabolic Risk Factors; Mental Health <br/><b>Sponsors</b>: National Institute of Environmental Health Sciences (NIEHS) <br/><b>Not yet recruiting</b>
Tue, 17 Nov 2026 00:00:00 EST

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
<b>Conditions</b>: Glioblastoma; Brain Tumor <br/><b>Interventions</b>: Drug: Sitagliptin <br/><b>Sponsors</b>: Case Comprehensive Cancer Center <br/><b>Recruiting</b>
Tue, 17 Nov 2026 00:00:00 EST

A Pilot Study of Small Fiber Neuropathy Prevalence in Fibromyalgia Patients Compared to Healthy Subjects Using Sudoscan®
<b>Conditions</b>: Fibromyalgia <br/><b>Interventions</b>: Device: Sudoscan® <br/><b>Sponsors</b>: University Hospital, Clermont-Ferrand <br/><b>Completed</b>
Tue, 17 Nov 2026 00:00:00 EST

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
<b>Conditions</b>: Metabolic Dysfunction-associated Steatohepatitis <br/><b>Interventions</b>: Drug: Efimosfermin alfa; Drug: Placebo <br/><b>Sponsors</b>: GlaxoSmithKline <br/><b>Recruiting</b>
Tue, 17 Nov 2026 00:00:00 EST

A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes
<b>Conditions</b>: Overweight; Obesity; Type 2 Diabetes Mellitus <br/><b>Interventions</b>: Drug: NNC0662-3168 (Test product-A); Drug: Placebo matched to NNC0662-3168 (Test product-A); Drug: Active Comparator (Product-B) <br/><b>Sponsors</b>: Novo Nordisk A/S <br/><b>Not yet recruiting</b>
Tue, 17 Nov 2026 00:00:00 EST

A Single-center, Open-label, Non-randomized Pilot Study of add-on Olmesartan 20 mg or 40 mg Daily, With the Dose Chosen According to Blood Pressure at Enrollment as in Routine Practice, Over 9 Months in Patients With Type 2 Diabetes and Albuminuria Who Were Already Receiving an SGLT2i.
<b>Conditions</b>: Type 2 Diabetes Mellitus; Diabetic Kidney Disease; Albuminuria <br/><b>Interventions</b>: Drug: Olmesartan <br/><b>Sponsors</b>: Tri-Service General Hospital (TSGH) <br/><b>Completed</b>
Tue, 17 Nov 2026 00:00:00 EST

A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
<b>Conditions</b>: Obesity <br/><b>Interventions</b>: Drug: eloralintide and tirzepatide; Drug: Eloralintide; Drug: Tirzepatide; Drug: Placebo <br/><b>Sponsors</b>: Eli Lilly and Company <br/><b>Not yet recruiting</b>
Tue, 17 Nov 2026 00:00:00 EST
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.

Latest Top (10) News


FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
Mon, 09 Nov 2026 17:15:46 EST

FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap
Thu, 05 Nov 2026 17:30:38 EST

FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality
The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.
Mon, 02 Nov 2026 08:56:06 EST

FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP).
Fri, 30 Oct 2026 16:32:08 EDT

FDA Launches New Program to Advance Neuroscience Medical Product Development
FDA announces the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aligned with the Trump Administration’s efforts to accelerate medical innovation and deliver breakthrough treatments.
Thu, 22 Oct 2026 12:58:19 EDT

FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
FDA today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis.
Tue, 20 Oct 2026 15:40:38 EDT

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women
Today, the U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week.
Tue, 20 Oct 2026 11:57:36 EDT

FDA Issues Final Guidance on Prescription Drug Apps and Software
The U.S. Food and Drug Administration today released final guidance establishing a clear framework for how drug companies can develop, distribute, and label apps used alongside their prescription medicines.
Tue, 20 Oct 2026 09:03:14 EDT

FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.
Mon, 19 Oct 2026 12:19:38 EDT

FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development
The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.
Wed, 14 Oct 2026 11:50:52 EDT